Satoru Takahashi

Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation

Although IFR and safety profiles were comparable between the two groups, EGFR mutation positivity was associated with a higher incidence of OFR, and these exploratory findings support the shift toward alternative systemic strategies, such as osimertinib, in patients with EGFR mutation-positive locally advanced unresect...